Genomic analysis has shown many variants in both CHRNA4 and CHRNB2, genes which encode the α4 and β2 subunits of nicotinic ACh receptors (nAChR) respectively. Some variants influence receptor expression, raising the possibility that CHRNA4 variants may affect response to tobacco use in humans. Chronic exposure to nicotine increases expression of nAChRs, particularly α4β2-nAChRs, in humans and laboratory animals. Here, we have evaluated whether the initial level of receptor expression affects the increase in expression.
Introduction
Tobacco use, primarily through cigarette smoking, is estimated to contribute annually to 4 000 000 deaths worldwide and nicotine is regarded as the component responsible for eliciting dependence. The initial sites of action of nicotine and related compounds are the nicotinic ACh receptors (nAChRs) for which ACh is the endogenous neurotransmitter. nAChR are ligand-gated ion channels assembled from five homologous subunits. Physiological and pharmacological properties of various nAChR subtypes are determined by the subunit composition of the receptor (Albuquerque et al., 2009; Fasoli and Gotti, 2015) .
Classical genetic analyses indicated that both genetic and environmental factors influence smoking behaviour (Hall et al., 2002) . Among the genes implicated in aspects of human smoking behaviour are nAChR variants. The most thoroughly documented genetic variants are in the CHRNA5 gene encoding the nAChR α5 subunit (Ware et al., 2011; Bierut et al., 2014) . Genetic studies also support roles for both CHRNA4 and CHRNB2 genes in aspects of tobacco use (Feng et al., 2004; Hutchison et al., 2007; Kamens et al., 2013; Esterlis et al., 2016; Melroy-Greif et al., 2016) . These genes encode the α4 and β2 nAChR subunits, which assemble into the most widely expressed subtype in the brain, the α4β2* nAChR (Millar and Gotti, 2009; Baddick and Marks, 2011) [* indicates potential additional subunits in the pentameric receptor (Lukas et al., 1999) ].
Genetic factors also contribute to variation in responses of mice to nicotine. Inbred mouse strains differ in their initial response to nicotine administration for which 35-40% of the variance may be explained by differences in nAChR expression (Marks et al., 1989; Damaj et al., 2007) . The development of genetically modified mice for which expression of either the α4 or β2 subunit (encoded by Chrna4 and Chrnb2, analogous to the human CHRNA4 and CHRNB2) has been deleted has established that both of these subunits are necessary for assembly of α4β2*-nAChRs (Picciotto et al., 1995; Marubio et al., 1999; Ross et al., 2000; Whiteaker et al., 2006; Baddick and Marks, 2011) . Expression of α4β2*-nAChRs is reduced, essentially in a gene dose-dependent fashion, in heterozygotes for either Chrna4 or Chrnb2 . The role of α4β2*-nAChRs in modulating aspects of nicotine-mediated responses has been demonstrated following deletion of either the α4 (Marubio et al., 1999) or β2 nAChR subunit (Marubio et al., 1999; Tritto et al., 2004) (reduced responsiveness to nicotine) or replacement of α4 by hypersensitive variants (Tapper et al., 2007) (increased responsiveness to nicotine).
More than 4000 variants in human CHRNA4 and 2000 variants in CHRNB2 have been identified (http://NCBI/SNP database-CHRNA4 and CHRNB2). The variants are located throughout these genes, many in non-coding regions. While variants in non-coding regions would not necessarily be expected to alter receptor function, they may influence expression of subunit proteins. Indeed, expression of human α4β2*-nAChRs varies widely (Breese et al., 1997 , Breese et al., 2000 , Cosgrove et al., 2012 , D'Souza et al., 2012 and individuals differing in receptor expression could respond differently to chronic tobacco use. Exposure to nicotine or tobacco increases levels of α4β2*-nAChR expression in rodents chronically exposed to nicotine (Marks et al., 1983; Schwartz and Kellar, 1983; Flores et al., 1992; Marks et al., 2011) , human tobacco users (Benwell et al., 1988; Breese et al., 1997; Perry et al., 1999; Staley et al., 2006) and cultured cells expressing α4β2*-nAChR natively or following transfection Lomazzo et al., 2011; Zambrano et al., 2012) . The current study was undertaken to investigate whether variation in the initial expression of α4β2*-nAChRs (achieved by deletion or partial deletion of the α4 and/or β2 subunits) affects the pattern and/or extent of the up-regulation of the receptors following chronic nicotine treatment.
Methods

Antibody production and characterization
Affinity-purified, subunit-specific, polyclonal antibodies (Abs) were used for the detection of nAChR subunits. The production of Abs complied fully with the guidelines established by the Italian Council on Animal Care and was approved by the Italian Government Decree No. 2/2010. Becuase the validity of the results presented in this paper strongly depend on the antibody used, we extensively characterized the specificity of the Abs for the different techniques that were used.
We used subunit-specific Abs that were produced in rabbits against peptides derived from the C-terminal (COOH) or intracytoplasmic loop (CYT) regions of the rodent (mouse and rat) or human subunit sequences, and affinity purified as previously described by Gotti et al. (2008) and Grady et al. (2009) . For the β2 subunit, we used the Abs directed against the rodent COOH (cgLHPDHSAPSSK) and the human β2 CYT (RQREREGAGALFFREAPGADSCTy) peptides. For the α4 subunit, we used the Abs directed against the rat CYT (PTSSPTSLKARPSQLPVSDQASPC) and COOH (PPWLAACI) peptides. For the α5 subunit, we used Abs directed against the mouse CYT (DRYFTQREEAESGAGPKSRNTLEAALD) and COOH (cgPVHIGNTIK) peptides. The specificity of the Abs was tested by immunoprecipitation and by Western blotting using tissues from α4, α5 and β2 from wild type (++), heterozygote (+À) and null mutant (ÀÀ) mice, as previously described (Gotti et al., 2008) . For the experiments reported here, we used Abs obtained from five rabbits immunized with human β2 CYT or rat CYT peptides, three rabbits immunized with the mouse α5 CYT peptide and two rabbits each immunized for the rodent β2, α4 and α5 COOH peptides.
Mice
All animal care and experimental procedures were reviewed and approved by the Institutional Animal Care and Utilization Committee of the University of Colorado Boulder and conformed to the guidelines of the NIH. Animal studies are reported in compliance with the ARRIVE guidelines (Kilkenny et al., 2010; McGrath and Lilley, 2015) .
Mice were chosen as the experimental model owing to the availability of animals differing in the expression of nAChR subunits (null mutants for the α4 and β2 nAChR subunit expression), which allowed the examination of differences in receptor expression on the regulation of these receptors by chronic nicotine treatment. Mice expressing the α4 nAChR null mutation were originally obtained from John Drago, University of Melbourne, Australia (Ross et al., 2000) . Mice expressing the β2 nAChR null mutation were originally obtained from Marina Picciotto, Yale University (Picciotto et al., 1995) . Each line has been backcrossed with C57BL/6J mice for at least 10 generations. Wild type (++), heterozygote (+À) and null mutant (ÀÀ) mice were generated by mating the appropriate heterozygotes. These heterozote matings were used to generate all ++, +À and -mice used for the experiments in this study. Offspring were genotyped using DNA extracted from tail clippings as described previously (Salminen et al., 2004) . Double heterozygote mice (α4 +À /β2 +À ) were generated by mating α4 and β2 null mutants. All mating and housing occurred in the specific pathogen-free colony at the Institute for Behavioural Genetics, University of Colorado Boulder. Before surgery, mice were housed with like sex littermates (two to five mice per cage) and maintained on a 12 h light/12 h dark cycle (lights on 07:00 h). Mice were allowed free access to food and water. Mice used for these experiments were between 60 and 120 days of age. The average weight of male mice was 27 g (range 19 to 36 g) and that of female mice was 22 g (range 17 to 28 g). A total of 621 mice were used for the experiments (329 males and 292 females. Eighty two were α4 ++ , 88 were β2 ++ , 97 were α4 +À , 93 were β2 +À , 90 were α4 +À / β2 +À , 65 were α4 and 105 were β2 ÀÀ ).
Chronic nicotine treatment
Methods previously described for continuous infusion (Marks et al., 1983; Marks et al., 2011) were followed with minor modifications. Mice were anaesthetised by intraperitoneal injection of a mixture of ketamine (100 mg·kg
À1
) and xylazine (10 mg·kg
). The right jugular vein was exposed, and a cannula constructed of silastic tubing (0.30 mm inner diameter, 0.64 mm outer diameter) filled with sterile isotonic saline containing 0.3% sodium citrate was inserted 8 mm into the vein and anchored to the underlying tissue with surgical silk thread. The silastic tubing was attached to 22 gauge stainless steel tubing affixed to a nylon circle (1 cm diameter), which was attached to the back of the mouse between the scapulae. Following surgery, each mouse was injected with 0.1 mg·kg À1 buprenorphine and placed in a freshly bedded cage. The mouse was warmed and monitored repeatedly until recovery from the anaesthetic. The day after surgery, the cannula was checked for free flow. The mouse was weighed and transferred to an infusion chamber (15 × 15 × 30 cm, l × w × h). Infusion chambers were constructed of black acrylic plastic with clear acrylic hinged plastic doors. Each infusion cage consisted of a bank of 12 infusion chambers arranged in two rows of six chambers. The infusion chamber was bedded with aspen wood chips and also included a cotton nesting block (nestlet). The stainless steel tubing was connected to polyethylene tubing connected to a Harvard Infusion pump that delivered isotonic sterile saline at a rate of 35 μL·h À1 . The polyethylene tubing was connected to a swivel dripper that permitted the mouse free movement within its cage. Saline infusion was maintained for 2 days before beginning drug treatment. Four treatment groups were used: saline-infused (controls), 0.25 mg·kg À1 ·h
nicotine, 1 mg·kg À1 ·h À1 nicotine and 4 mg·kg À1 ·h À1 nicotine. Liquid nicotine that had been redistilled was used for the chronic treatments. Nicotine solutions were neutralized with HCl before administration. Nicotine doses are calculated as free base. Mice were treated for 10 days after which time treatment was discontinued.
As the study included mice of seven genotypes and four nicotine treatment doses, there were 28 different treatment conditions. Based on previous studies, the original design specified a group size of six. Mice were assigned randomly by sex to each of the four treatment groups within each of the seven genotypes. However, it should be noted that at the completion of the experiments, the numbers of mice in each group varied somewhat and consequently differ from the ideal that treatment groups contain equal numbers. In part, this variability in group number was intentional as results for one group in particular (α4 +À ) were quite unusual.
It was deemed necessary to add more animals to this group to examine whether this response was correct. Some variability in group numbers also occurred because occasional regenotyping changed the placement of mice originally assigned to a treatment group. On some occasions, occasional loss of mice during treatment may have skewed group sizes.
Autoradiographic measurement of [ 125 I] epibatidine binding
Two hours after nicotine administration, mice were killed by cervical dislocation and decapitated. The brain was removed from the skull and frozen by immersion in isopentane (À30°C). The frozen brain was wrapped in aluminium foil and stored at À70°C until sectioning.
Preparation of tissue sections. On the day of sectioning, a brain was removed from the À70°C freezer and allowed to warm to the temperature of the cryostat (À14°C). The brain was subsequently mounted on the cryostat chuck with M-1 Embedding Matrix (Anatomical Pathology, Pittsburgh, PA, USA). Subsequently, coronal sections (14 μ thick) were obtained using either a Leica CM 1850 cryostat/microtome (Leica, Nussloch, Germany) in buffer that also included 50 nM cytisine to selectively inhibit primarily α4β2*-nAChR binding sites (Marks et al., 1998) . A third set of slides with representative mice from each treatment group was incubated with the [ 125 I]-epibatidine in buffer that also included 10 μM nicotine to establish blanks. Samples were incubated for 2 h at 22°. Following the incubation, the slides were redistributed to slide racks containing 25 slides and washed as follows (all solutions at 4°C): Twice for 30 s in isotonic buffer, twice for 5 s in hypotonic buffer (0.1×) and twice for 5 s in 10 mM HEPES, pH = 7.5. The samples were air dried and stored overnight under vacuum at room temperature in a desiccator. The dried slides were apposed to Perkin-Elmer Packard Super Resolution Cyclone Storage Phosphor Screens for 7-14 days to yield images for quantitation. Each Phosphor Screen was also simultaneously exposed to a series of tissue paste standards containing measured amounts of 125 I to allow quantitation of the image intensity. Blanks determined by incubation in the presence of 10 μM nicotine did not differ significantly from film background.
Quantitation of signal intensity
Tissue paste samples prepared from whole brain homogenates and containing measured amounts of 125 I were used to construct standard curves. The standards were prepared such that the standard with the highest amount of ). Brain regions were identified using a mouse brain atlas (Franklin Keith and Paxinos, 1997) . Several measurements were made in each brain region of every mouse, and the average of these measurements defined the signal intensity for each region of each subject.
Blinding during analysis. In order to maintain accurate records, it was necessary to label the printout of each scan with identifiers for each animal including genotype, dose and mouse coding number (to allow re-genotyping if needed). However, that information was not taken into account during measurement of signal intensity on each screen until the analysis was complete. Measurements were made in a defined order on each screen. First, the signal intensity of the standards was measured. Subsequently, signal from each mouse was measured for the brain areas proceeding from the anterior sections to the posterior sections of that mouse. That pattern was repeated for sections of each mouse on screen. After data collection and calculation, values for each experiment were entered into the appropriate data sheets. In order to achieve as much consistency as possible for the imaging studies, frequently but not always, microscope slides with samples from each of the treatment groups for a single genotype were included on a screen (there is space to accommodate slides from four different treatments). As noted above, each screen also included a set of 125 I standards.
Immunochemical analysis of nAChR subunits
Following chronic treatment and 2 h withdrawal, mice were killed by cervical dislocation, their brains removed, frozen by immersion in isopentane (À30°C), wrapped in aluminium foil and stored at À70°C before transfer to Milan, Italy.
Tissue homogenates
The particulate fractions from whole mouse brains were washed copiously with 0.32 M sucrose 10 mM À1 TRIS buffer and homogenized in the same sucrose/Tris buffer using an Ultraturrax homogenizer and glass-Teflon tissue grinder.
Triton X-100 extracts
The particulate fractions from whole mouse brains of the various treatment groups were washed by centrifugation in the Tris-HCl 50 mM, NaCl 120 mM, KCl 5 mM, MgCl 2 1 mM, CaCl 2 2.5 mM, pH 7.5 buffer by centrifugation. The resulting pellets were suspended in the same buffer containing 2% Triton X-100. Extraction was performed for 2 h at 4°C as previously described (Moretti et al., 2010) . Protein content of the membranes and 2% Triton X-100 extracts was measured using the bicinchonic acid protein assay (Pierce, Rockford, IL, USA) with bovine serum albumin as the standard.
[ 3 H]-Epibatidine binding studies
After incubating, the samples from each of the different groups with 1 μM α-bungarotoxin for 2 h (in order to block binding of 3 H-epibatidine to α7-nAChR sites), binding experiments were carried out by incubating aliquots of the membranes or the extracts with 1 nM [ 3 H]epibatidine for 2 h at 20°C. Non-specific binding (average of 5-10% of total binding) was determined in parallel samples containing 100 nM unlabelled epibatidine. At the end of the incubation, the samples were filtered on a Millipore apparatus using a glass GFC filter soaked in 0.5% polyethylenimine, washed with 15 mL of buffer solution (sodium phosphate, 10 mM, pH 7.4 and 50 mM NaCl) and counted in a Tri-Carb 2100TR β-counter (Perkin Elmer). Extracts were incubated overnight (14 h) with 1 nM [ 3 H]-epibatidine at 4°C. Following the overnight incubation, receptors were captured using DEAE-Sepharose ™ Fast flow (GE Healthcare, Uppsala, Sweden). The bound receptors were eluted with 1 N NaOH and after addition of the scintillation mixture (filter count, GE Healthcare, Uppsala, Sweden) counted in a Tri-Carb 2100TR β-counter (Perkin Elmer) counter. Non-specific binding (averaging 5-10% of total binding) was determined in parallel samples containing 100 nM unlabelled epibatidine.
Immunoprecipitation of [ 3 H]-epibatidinelabelled receptors by subunit-specific antibodies
The extracts (100-150 μL) obtained from whole brain were incubated with 1 μM α-bungarotoxin followed by incubation with 1 nM [
3 H]-epibatidine and then incubated overnight with a saturating concentration of affinity purified antisubunit IgG (anti-α4, -α5 or -β2) (10 μg) bound to SepharoseProteinA (GE Healthcare, Italy). Immunoprecipitates were recovered by centrifugation (5 min at 2500 × g). The level of Ab immunoprecipitation was expressed as fmol of immunoprecipitated receptors per mg protein and is the mean ± SEM of two to three replicates for each individual sample.
Immunoblotting and densitometric quantification of Western blot bands
The nAChR subunits were analysed by Western blotting as described previously (Gotti et al., 2008; Grady et al., 2009) . In brief, for whole brain, homogenates of the different groups were loaded, separated by means of SDS-polyacrylamide gel electrophoresis using 9% acrylamide and electrophoretically transferred to nitrocellulose membranes with 0.45 mm pores (Schleicher and Schull ll, Dassel, Germany). The blots were blocked overnight with 4% non-fat milk powder in Tris-buffered saline, washed with buffer containing 4% non-fat milk and 0.3% Tween20 in Tris-buffered saline and incubated for 2 h with the primary antibody directed against the α4 and β2 CYT peptides at the concentration of 5 μg·mL À1 . Blots were then incubated for 1 h with the appropriate secondary antibody (anti-rabbit Ly-Cor IRDye800RD). After six washes of 5 min each in Tris-buffered saline with 0.3% Tween 20, the membranes were dried overnight in the dark at room temperature. The infrared signal was measured using an Odyssey CLx -Infrared Imaging System. The signal intensity of the Western blot bands was quantified using iStudio software. The response of both the α4 and β2 subunits to nicotine treatment for mice of each genotype was calculated as the ratio between the signal for the nicotine-treated mice and saline-treated mice of the same genotype. The optical density of the saline-treated mice of each genotype was set at 100%. The data are expressed as mean values ± S.E.M. of 68 (homogenates) independent preparations. Each preparation was analysed two to three times in separate experiments for each antibody to obtain the mean value for each preparation.
The mean values of the saline-treated mice for the α4 ++ and β2 ++ genotypes were as follows: α4 subunit (1 ± 0.13; 1 ± 0.12), β2 subunit (1 ± 0.11; 1 ± 0.11). For the α4 +À and β2 +À genotypes were as follows: α4 subunit (1 ± 0.12; 1 ± 0.12), β2 subunit (1 ± 0.12; 1 ± 0.13). For α4 +À /β2 +À genotype was as follows: α4 subunit (1 ± 0.12), β2 subunit (1 ± 0.11).
Data and statistical analysis
The data and statistical analysis comply with the recommendations on experimental design and analysis in pharmacology (Curtis et al., 2015) . Considering past experience with studies such as those described in the current study, a minimum group size of n = 5 was chosen, and upon final analysis, most groups exceeded this minimum number. However, some differences in group sizes occurred. Each group size is specified in the legends for the 
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www. guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Southan et al., 2016) , and are permanently archived in the Concise Guide to PHARMACOLOGY 2015/16 .
Results
Epibatidine binding following deletion or partial deletion of the α4 or β2 nAChR genes
Deletion and/or partial deletion of α4 and/or β2 nAChR subunits reduces cytisine-sensitive [ 125 I]-epibatidine binding in a gene-dose-dependent manner (Supporting Information  Fig. S1 ). Significant binding persists in several brain regions known to contain high expression of non-α4β2*-nAChR. Supporting Information Fig. S2 summarizes the effect of deletion of α4 and/or β2 nAChR genes on expression of α4, β2 and α5 nAChR proteins measured by immunoprecipitation with subunit selective antibodies. (Marks et al., 1983; Marks et al., 2004; Marks et al., 2011) . Brain areas for which no significant overall effect of nicotine treatment was observed were clustered in four thalamic nuclei, the habenular-interpeduncular nucleus pathway (three nuclei) and in four areas related to the visual pathway. In order to evaluate the overall effects of chronic nicotine treatment as a function of nicotine treatment dose and genotype, scattergrams were constructed comparing the changes from control binding for mice differing in α4 and/or β2 nAChR gene expression (Figure 1 ). Each data point represents the calculation for an individual brain region as ratio of the binding for nicotine-treated mice to that of saline-treated mice. The line of unit slope that bisects each panel is expected if response to chronic nicotine treatment for each mutant is the same as that for wild-types. These analyses omitted results for medial habenula, fasiculus retroflexus and interpeduncular nucleus. Figure 1A- 
Western blot analysis of α4 and β2 nAChR subunits as a function of nicotine treatment and genotype
As immunoprecipitation experiments demonstrated an increase in α4β2-nAChR subtype in whole brains of α4 ++ , β2 ++ , α4 +À , β2 +À and α4 +À /β2 +À mice accounted for the increase of [ 3 H]-epibatidine binding sites, the effect of nicotine treatment on expression of α4 and β2 subunits was analysed using quantitative Western blotting shown in Figure 3 . Results were normalized to those of saline-treated mice within each genotype and subunit probe. Briefly, quantitative Western blotting for nAChR subunits detected with anti-α4 or anti-β2 selective antibodies demonstrates that both subunits increase following chronic nicotine treatment with a tendency for greater increases in α4 +À and α4 +À /β2 +À brains than for wild-type or β2 +À brains. Western blotting for α4 nAChR protein demonstrated significant effect of chronic nicotine treatment (F 3, 160 = 36.37), but not of genotype (F 4, 160 = 0.99). The significant genotype by nicotine treatment interaction (F 12, 160 = 2.29) suggested a potential difference in the pattern of response to chronic nicotine treatment among the groups. Western blotting for β2 nAChR protein yielded results similar to those observed for α4 nAChR subunit protein: significant effect of nicotine treatment ( Nicotine dose α4 7,7,7 6,7,5 8,7,6 7,7,6 8,8,8 6,6,6 5,5,5 0.25 mg·kg À1 ·h À1 7,7,7 6,5,5 8,9,8 6,6,6 6,6,6 6,6,6 6,7,7 7,5 5,6,5 9,9,7 7,7,6 8,8,8 8,8,5 7,7,7 4.0 mg·kg À1 ·h À1 7, 8,6 6,6,5 8,9,7 7,6,6 7,7,7 7,7,7 5,5,5 Representative Western blots probed with either anti-α4 or anti-β2 antibodies are shown in Figure 3A , D for α4 ++ and β2 ++ mice respectively. Normalized subunit signal intensities as a function of nicotine treatment dose are presented in Figure 3B , E for α4 ++ and Figure 3C , F for β2 ++ mice, for the α4 and β2 nAChR subunit proteins respectively. The responses of α4 ++ and β2 ++ mice were very similar both for pattern of response to chronic nicotine treatment and for relative increases in both α4 and β2 subunit expression (compare Figure 3B with Figure 3E for α4 and Figure 3C with Figure 3F for β2; two-way ANOVAs for α4 nAChR subunit protein: significant main effect of nicotine-F 3,44 = 16.65, but not of genotype-F 1,44 = 0.14 or nicotine by genotype interaction-F 3,44 = 0.16 and for the β2 nAChR subunit protein: significant main effect of nicotine-F 3,56 = 21.07 but not of genotype-F 1,56 = 0.003 or nicotine by genotype interaction-F 3,56 = 0.055). Subsequent analysis of the effect of nicotine treatment by one-way ANOVA showed significant effects for both α4 ++ mice (for α4 signal, F 3, 29 = 25.08; for β2 signal, F 3, 30 = 11.46) and β2 ++ mice (for α4 signal, F 3, 28 = 24.38; for β2 signal, F 3, 28 = 18.23). Expression of both subunit proteins attained near maximal increases following treatment with 1.0 mg·kg À1 ·h À1 nicotine. The relative percentage increases in expression of α4 subunit protein following treatment with 4.0 mg·kg À1 ·h À1 nicotine (69 ± 7% and 67 ± 9% for α4 ++ and β2 ++ mice, respectively) were slightly, but not significantly, greater than the relative percentage increases in β2 subunit protein (52 ± 9% and 53 ± 9% for α4 ++ and β2 ++ mice, respectively). Representative Western blots probed with either anti-α4 or anti-β2 antibodies for α4 +À mice are shown in Figure 3G and for β2 +À mice in Figure 3J and α4 and β2 subunit signal intensity as a function of nicotine dose are presented in Figures 3H, I for α4 +À mice and 3 K and 3 L for β2 +À mice respectively.
For α4 +À mice, statistically significant increase in the expression of α4 nAChR subunit protein as a function of
Figure 3
Quantitative Western blotting to measure expression of α4 and β2 subunit protein following chronic nicotine treatment of mice differing in nAChR expression. Relative levels of α4 and β2 nAChR subunit proteins were measured by quantitative Western blotting for α4
+À and α4 +À /β2 +À mice chronically treated for 10 days saline, 0.25, 1.0 or 4.0 mg·kg À1 ·h À1 nicotine as described in the Methods section. The top panels show representative blots. The middle panels (red points and lines) show the relative effects of chronic nicotine treatment on α4 subunit levels. The lower panels (blue points and lines) show the relative effects of chronic nicotine treatment on β2 subunit levels. All data points have been normalized to the expression level measured for saline-treated mice. Errors for the saline-treated mice are summarized in the Methods section and all fall within the symbols. The mean values of the saline-treated mice for the α4 ++ and β2 ++ genotypes were α4 subunit (1 ± 0.13; 1 ± 0.12) and β2 subunit (1 ± 0.11; 1 ± 0.11); for the α4 +À and β2 +À genotypes were α4 subunit (1 ± 0.12; 1 ± 0.12) and β2
subunit (1 ± 0.12; 1 ± 0.13); and for α4 +À /β2 +À genotype were α4 subunit (1 ± 0.12) and β2 subunit (1 ± 0.11). Each point is the mean ± SEM of six to eight separate mice. Numbers in the table are the number of mice analysed. Each mouse has been tested at least three times with different anti-α4 or anti-β2 CYT Abs.
Nicotine dose α4
nicotine treatment dose was observed (F 3, 32 = 7.85) . This increase appears saturable with a 58 ± 18% increase following treatment with 4.0 mg·kg À1 ·h À1 nicotine. This pattern is similar to that noted for wild-type mice. A statistically significant increase in the expression of the β2 nAChR subunit protein as a function of nicotine treatment was also noted (F 3, 32 = 14.91) . However, expression of β2 continues to increase with nicotine treatment dose attaining a 91 ± 22% increase following treatment with 4.0 mg·kg À1 ·h À1 nicotine. The response to chronic nicotine treatment for β2 +À mice was similar to that observed for wild-type mice. Statistically significant increases in expression of α4 (F 3, 37 = 18.00) and β2 (F 3, 36 = 7.60) nAChR subunit proteins as a function of nicotine treatment dose were observed. These increases appear saturable with a 67 ± 9% increase for α4 subunit and a 49 ± 9% increase for β2 subunit following treatment with 4.0 mg·kg À1 ·h À1 nicotine.
Representative Western blots probed with either anti-α4 or anti-β2 antibodies for α4 +À /β +À mice are shown in Figure 3M , and α4 and β2 subunit signal intensity as a function of nicotine treatment dose is presented in Figure 3N , O respectively. 
Discussion
Effects of deletion or partial deletion of the α4 and β2 nAChR subunits on the expression of α4β2*-nAChR and their response to chronic nicotine treatment are reported. Particularly, striking was a more robust relative up-regulation of α4β2-nAChR following chronic nicotine treatment in mice with reduced expression of the α4 subunit (α4 +À and α4 +À / β2 +À mice).
Autoradiographic and immunochemical analysis of epibatidine binding: effect of α4 and/or β2 deletion or partial deletion
Consistent with previous reports for the β2 nAChR subunit (Picciotto et al., 1995; Baddick and Marks, 2011) or the α4 nAChR subunit (Marubio et al., 1999; Ross et al, 2000; Marks et al., 2007; Baddick and Marks, 2011) or β2 nAChR subunits were generally similar, deletion of the β2 subunits had a greater effect on binding than deletion of α4 subunits in basal ganglia and visual tracts reflecting the presence of α6β2*-nAChR and/or α3β2*-nAChR (Whiteaker et al., 2000; Champtiaux et al., 2002; McClure-Begley et al., 2012) . Significant [ 125 I]-epibatidine binding persisted in medial habenula, fasciculus retroflexus and interpeduncular nucleus of knockout mice reflecting the limits of cytisine inhibition specificity in regions with high numbers of cytisine-resistant sites (Marks et al., 1998; Perry et al., 2002) . As noted previously Marks et al., 2007) unit. Predominant α4β2α5-nAChR composition expressed in mouse brain contrasts with that for nAChR expression in the autonomic nervous system where α3β4α5-nAChR or, to a lesser extent, α3β2α5-nAChR, predominate (Wang et al., 1996; Garza et al., 2009) . However, α5 is expressed in small numbers in non-α4β2*-nAChR subtypes in brain regions such as medial habenula and interpeduncular nucleus (Grady et al., 2009) .
Chronic nicotine treatment
Chronic nicotine treatment up-regulated cytisine-sensitive [ 125 I]-epibatidine binding sites measured autoradiographically for wild-types. Up-regulation varied among brain regions as reported previously Marks et al., 2011 . Quantitative immunoprecipitation and Western blot analyses measured for wild-type mice also confirmed that chronic nicotine treatment increased subunit expression and reinforce previous observations that increased binding sites are α4β2*-nAChR (Flores et al., 1992) . Results obtained with anti-α5 antibody for wild-type mice are also consistent with previous reports that α5*-nAChR do not markedly increase following chronic nicotine treatment (Mao et al., 2008; Gahring and Rogers, 2010) . However, α5*nAChR in cell lines have been reported to up-regulate following nicotine treatment (Kuryatov et al., 2008) . Deletion of either subunit virtually eliminated epibatidine binding measured autoradiographically or by immunoprecipitation. Nicotine treatment had no effect on these parameters in null mutants. mice, their response to chronic nicotine treatment was qualitatively very similar to that for wild-type mice as noted previously (McCallum et al., 2006) . Furthermore, quantitative Western blotting for β2 +À mice revealed a pattern of response to chronic nicotine treatment similar to that for wild-type mice. These results indicate that, despite a shift in stoichiometry favouring higher expression of (α4) 3 (β2) 2 -nAChR (Nelson et al., 2003; Moroni et al., 2006; Gotti et al., 2008) Immunoprecipitation by both the anti-α4 and anti-β2 antibodies and Western blotting to measure α4 and β2 nAChR subunit proteins confirmed this difference. Relatively more receptors with the (α4) 2 (β2) 3 -nAChR stoichiometry persist in α4 +À mice (Nelson et al., 2003; Moroni et al., 2006; Gotti et al., 2008) Quantitative Western blotting also indicates that chronic nicotine treatment elicits a significantly higher percentage increase of both α4 and β2 subunits for α4 +À β2 +À mice than observed for mice of any other genotype.
As was the case with wild-type mice and consistent with previous reports, little relative change in α5*-nAChR expression (mostly α4β2α5-nAChR) occurred following chronic nicotine treatment for any mice differing in initial expression of the α4 or β2 nAChR subunit proteins.
Interpretation
Expression of α4β2*-nAChR varies among individuals. For example, SPECT scans of non-smokers using 5-[
123 I] A85380
to measure β2*-nAChR reported at least a fourfold range in signal intensity (Cosgrove et al., 2012; D'Souza et al., 2012) . A similar variability was reported in post mortem samples (Breese et al., 2000) . Variations in binding site densities were also observed for up-regulated sites in smokers. Furthermore, less up-regulation of high affinity nAChR binding sites was noted for schizophrenic smokers than for non-schizophrenic smokers despite the observation that schizophrenics were heavier smokers (Breese et al., 2000; D'Souza et al., 2012) . Perhaps, differences in responses of controls and schizophrenic individuals could arise from variation in relative expression of α4 or β2 subunits.
As noted in the Introduction, genetic factors have been shown to influence aspects of tobacco smoking behaviour. Results of this study with a mouse model that provides lowered initial expression of α4 and/or β2 nAChR subunit proteins indicate that differences in expression, particularly for the α4 subunit, alter the relative extent of up-regulation in response to chronic nicotine treatment. Variants in human genes, particularly CHRNA4, may affect initial levels of nAChR expression in a manner analogous to that observed for mice by partial gene deletion in the mouse model. Genetic variation in individual humans could result in differences in receptor regulation following tobacco use and subsequently affect dependence and withdrawal from chronic nicotine exposure.
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https://doi.org/10.1111/bph.13896 Figure S1 Effect of deletion or partial deletion of the α4 and/or β2 nAChR subunits examined autoradiographically. Figure S2 Effect of deletion or partial deletion of the α4 and/or β2 nAChR subunits examined by immunoprecipitation. 
